Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men

Purpose: The aim of this study was to compare the frequency of ERG rearrangement, PTEN deletion, SPINK1 overexpression, and SPOP mutation in prostate cancer in African American and Caucasian men. Experimental design: Dominant tumor nodules from radical prostatectomy specimens of 105 African American men (AAM) were compared with 113 dominant nodules from Caucasian men (CaM). Clinical and pathologic characteristics of the two groups were similar. SPINK1 overexpression was evaluated by immunohistochemistry, ERG rearrangement and PTEN deletion by FISH, and SPOP mutation by Sanger sequencing. Results: ERG rearrangement was identified in 48 of 113 tumors (42.5%) in CaM and 29 of 105 tumors (27.6%) in AAM (P = 0.024). PTEN deletion was seen in 19 of 96 tumors (19.8%) in CaM and 7 of 101 tumors (6.9%) in AAM (P = 0.011). SPINK1 overexpression was present in 9 of 110 tumors (8.2%) in CaM and 25 of 105 tumors (23.4%) in AAM (P = 0.002). SPOP mutation was identified in 8 of 78 (10.3%) tumors in CaM and 4 of 88 (4.5%) tumors in AAM (P = 0.230). When adjusted for age, body mass index, Gleason score, and pathologic stage, ERG rearrangement and SPINK1 overexpression remain significantly different (P = 0.018 and P = 0.008, respectively), and differences in PTEN deletion and SPOP mutation approach significance (P = 0.061 and P = 0.087, respectively). Conclusions: Significant molecular differences exist between prostate cancers in AAM and CaM. SPINK1 overexpression, an alteration associated with more aggressive prostate cancers, was more frequent in AAM, whereas ERG rearrangement and PTEN deletion were less frequent in this cohort. Further investigation is warranted to determine whether these molecular differences explain some of the disparity in incidence and mortality between these two ethnic groups. Clin Cancer Res; 20(18); 4925–34. ©2014 AACR.

[1]  John T. Wei,et al.  Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. , 2013, Urologic oncology.

[2]  A. Zoubeidi,et al.  Dual inhibition of autophagy and the AKT pathway in prostate cancer , 2013, Autophagy.

[3]  M. Rubin,et al.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover , 2013, Proceedings of the National Academy of Sciences.

[4]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[5]  Aliccia Bollig-Fischer,et al.  Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[6]  U. Stenman,et al.  A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells , 2013, Prostate Cancer and Prostatic Diseases.

[7]  Michael N. Ferrandino,et al.  Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center , 2012, Prostate Cancer and Prostatic Diseases.

[8]  M. Truong,et al.  Toward the detection of prostate cancer in urine: a critical analysis. , 2013, The Journal of urology.

[9]  John T. Wei,et al.  Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. , 2012, American journal of clinical pathology.

[10]  S. Srivastava,et al.  Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. , 2012, Urology.

[11]  W. Hahn,et al.  Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis , 2012, Proceedings of the National Academy of Sciences.

[12]  J. Hicks,et al.  Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer , 2012, Modern Pathology.

[13]  T. Clackson,et al.  Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models , 2012, International journal of oncology.

[14]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[15]  M. Soloway,et al.  Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. , 2012, The Journal of urology.

[16]  J. Squire,et al.  Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration‐resistant prostate cancer , 2012, Histopathology.

[17]  Nallasivam Palanisamy,et al.  Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.

[18]  J. Squire,et al.  PTEN deletion and heme oxygenase‐1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome , 2011, The Journal of pathology.

[19]  S. Freedland,et al.  Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men , 2011, Prostate Cancer and Prostatic Diseases.

[20]  B. O’Malley,et al.  Tumor Suppressor Role for the SPOP Ubiquitin Ligase in Signal-Dependent Proteolysis of the Oncogenic Coactivator SRC-3/AIB1 , 2011, Oncogene.

[21]  M. Rubin,et al.  TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients , 2011, The Prostate.

[22]  S. Varambally,et al.  Therapeutic Targeting of SPINK1-Positive Prostate Cancer , 2011, Science Translational Medicine.

[23]  J. D’Armiento,et al.  Tuberculosis Immunopathology: The Neglected Role of Extracellular Matrix Destruction , 2011, Science Translational Medicine.

[24]  J. Squire,et al.  PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer , 2011, BJU international.

[25]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[26]  V. Apprey,et al.  Identification of Differentially Methylated Genes in Normal Prostate Tissues from African American and Caucasian Men , 2010, Clinical Cancer Research.

[27]  Tapio Visakorpi,et al.  Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate Cancer , 2010, Clinical Cancer Research.

[28]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[29]  J Wade Harper,et al.  Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. , 2009, Molecular cell.

[30]  B. O’Malley,et al.  Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family , 2009, Nature Reviews Cancer.

[31]  Arul M Chinnaiyan,et al.  Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States , 2009, Clinical Cancer Research.

[32]  O. Ludkovski,et al.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.

[33]  John T. Wei,et al.  The role of SPINK1 in ETS rearrangement-negative prostate cancers. , 2008, Cancer cell.

[34]  U. Stenman,et al.  Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. , 2007, European urology.

[35]  M. Shen,et al.  Pten inactivation and the emergence of androgen-independent prostate cancer. , 2007, Cancer research.

[36]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[37]  T. Kute,et al.  Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[38]  A. Ziaee,et al.  Role of PTEN gene in progression of prostate cancer. , 2007, Urology journal.

[39]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[40]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[41]  W. Isaacs,et al.  Explaining racial differences in prostate cancer in the United States: Sociology or biology? , 2005, The Prostate.

[42]  Desok Kim,et al.  Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. , 2003, The Journal of urology.

[43]  C. Longcope,et al.  Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[44]  Simon P. Kim,et al.  Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  E. Rimm,et al.  Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. , 2000, Journal of the National Cancer Institute.

[46]  M. Banerjee,et al.  Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease. , 2000, Urology.

[47]  永井康雄 Identification of a novel nuclear speckle-type protein,SPOP(新規核speckle型タンパク質,SPOPの同定) , 1998 .

[48]  永井 康雄 Identification of a novel nuclear speckle-type protein, SPOP , 1998 .

[49]  G. A. Alexander,et al.  Prostate cancer treatment outcome in blacks and whites: a summary of the literature. , 1998, Seminars in urologic oncology.

[50]  Y. Muro,et al.  Identification of a novel nuclear speckle‐type protein, SPOP , 1997, FEBS letters.

[51]  L. Bernstein,et al.  Serum testosterone levels in healthy young black and white men. , 1986, Journal of the National Cancer Institute.

[52]  M. Streitwieser,et al.  Explaining Racial Differences , 1983 .